Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · CA, MA, OH, NJ, United Kingdom (as filed: X0), NH, NC, NY · Sep 29, 2008 → Feb 14, 2023
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 3:01 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Michael Ross is listed as an executive officer and director on 64 SEC Form D filings by 30 issuers between Sep 2008 and Nov 2025. Largest by amount reported sold: SV Life Sciences Fund IV CF, L.P. (Boston, MA — pooled investment fund — 2022; $421.4M reported sold to 44 investors), SV LIFE SCIENCES FUND V LP (Boston, MA — pooled investment fund — 2010; $407.2M reported sold to 42 investors), SV Life Sciences Fund VI, L.P. (Boston, MA — pooled investment fund — 2015–2016; $273.5M reported sold to 24 investors), CATABASIS PHARMACEUTICALS INC (Boston, MA — pharmaceuticals — 2010–2015; $175.7M reported sold to 23 investors), Xilio Therapeutics, Inc. (Waltham, MA — biotechnology — 2021; $95M reported sold to 17 investors) and 25 more (all listed below).
What this means That is a lot of deals — 30 separate companies raised money with this person listed as executive officer and director, over about 17 years. Across those companies the filings report $2.07B sold in total.
Listed alongside Tillman U. Gerngross (15 shared filings), Terrance McGuire (12 shared filings), Carl L. Gordon (9 shared filings), Claudio Nessi (9 shared filings), Errik Anderson (9 shared filings) and 192 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Michael. Each name links to their own page.
The issuers belong to 4 sponsor groups: Sv Life Sciences (10 issuers, $1.56B reported sold, 2010–2026), Adimab (2 issuers, $17.8M reported sold, 2009–2012), X4 Pharmaceuticals (2 issuers, $120M reported sold, 2010–2025) and Strength (16 issuers, $375.1M reported sold, 2010–2025).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 5 court cases matching the name, 1 state regulator order, 92 bankruptcy cases matching the name listed in Key records below.
What this means 98 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared the newest 50 of 64 public filings for Michael Ross and found 19 differences, 2 worth asking the sponsor about: Michael Ross appears on 4 deals that stopped filing before reaching their target; 9 Form Ds were filed more than 15 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Michael Ross has not run yet — it is #24,306 of 38,984 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.
Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.
Five things investors ask first. Items still in human review are counted, not shown.
5 cases: 5 closed (disposition not in docket feed)
Other Statutory Actions· Cause:
28:2201 Constitutionality of State Statute(s)
370 Other Fraud· Cause:
28:1331 Fed. Question
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 3:01 AM ET.
Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
1 state regulator order
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Michael Ross..
State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).
92 cases: 4 open, 88 closed (disposition not in docket feed)
68 Dischargeability - 523(a)(6), willful and malicious injury
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 3:01 AM ET.
Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
19 differences found between the filings for Michael Ross — 2 worth asking about (compared the newest 50 of 64 filings on Oct 24, 2026; older filings not covered)
United States Bankruptcy Court, C.D. California docket "Leslie E. Schulze" filed Jul 23, 2009, closed Jan 21, 2010. Leslie Schulze (listed on the same filings) is listed as Debtor ("Leslie E. Schulze"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, C.D. California docket "WELLS FARGO BANK, N.A. v. Shanafelt" filed Apr 3, 2008, closed Jul 23, 2008. Armen Shanafelt (listed on the same filings) is listed as Defendant ("Shanafelt"). Our match estimate: 68%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
The Feb 23, 2012 Form D reports $2,000,000 sold and $260,000 of the proceeds used for payments to officers, directors or promoters (marked as an estimate).
What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.
SV7 Impact Medicine Fund LP (last filing Jun 25, 2019; $0 sold of $250,000,000); Ophthotech Corp. (last filing Nov 2, 2018; $16,666,668 sold of $50,000,000); Dementia Discovery LP (last filing Oct 17, 2017; $25,967,331 sold of $302,381,000); THESAN PHARMACEUTICALS, INC. (last filing Feb 24, 2014; $17,399,999 sold of $49,513,148). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Form D filed 134 days after the first sale — Dualitas Therapeutics, Inc. · Form D filed 224 days after the first sale — SV Life Sciences Fund IV CF, L.P. · Form D filed 107 days after the first sale — Lucina Health, Inc. · Form D filed 232 days after the first sale — Lucina Health, Inc. · Form D filed 19 days after the first sale — TRex Holdings Inc. · and 4 more
What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.
No amendment in the last 12 months on an offering that may still be open — Therini Bio, Inc. (latest filing Sep 8, 2025) · No amendment in the last 12 months on an offering that may still be open — TRex Holdings Inc. (latest filing Nov 26, 2024) · No amendment in the last 12 months on an offering that may still be open — Andovia Inc. (latest filing Feb 14, 2023) · No amendment in the last 12 months on an offering that may still be open — Ribometrix, Inc. (latest filing Nov 19, 2018) · No amendment in the last 12 months on an offering that may still be open — Ophthotech Corp. (latest filing Nov 2, 2018) · and 10 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
Offering amount changed between filings — Therini Bio, Inc. · Offering amount changed between filings — Therini Bio, Inc. · Offering amount changed between filings — SUTRO BIOPHARMA INC · Offering amount changed between filings — Dementia Discovery LP · Offering amount changed between filings — Deciphera Pharmaceuticals, LLC · and 1 more
What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.
The May 17, 2019 filing lists a minimum of $690,072; the May 22, 2020 Form D/A lists $1.
What this means A different minimum usually means the offering terms changed. Check which terms apply to you.
listed as "Michael Ross" on 49 filings (from Nov 29, 2010), and "Michael Jay Ross" on the Aug 19, 2021 filing.
What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.
"Biotechnology" (Mar 15, 2013 to Aug 6, 2015); then "Pharmaceuticals" (Jun 27, 2017).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
"Pharmaceuticals" (Sep 29, 2015 to Jul 14, 2016); then "Biotechnology" (Jun 5, 2017).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
"Pooled Investment Fund" (Sep 29, 2016); then "Retailing" (Oct 14, 2016).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
This page covers filings where the address state is CA or MA or OH or NJ or X0 or NH or NC or NY. A separate record, "Michael F. Ross" with address state OK, is listed on 6 filings — most recently by INSURICA INSURANCE SERVICES, LLC (Apr 8, 2026). Both records have filings in the same period (Oct 27, 2015 to Feb 14, 2023).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is CA or MA or OH or NJ or X0 or NH or NC or NY. A separate record, "Michael P. Ross" with address state TX, is listed on 2 filings — most recently by Jason Ryan (Sep 24, 2019). Both records have filings in the same period (Mar 11, 2015).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is CA or MA or OH or NJ or X0 or NH or NC or NY. A separate record, "Michael A. Ross" with address state VA, is listed on 1 filing — most recently by Euclid Systems Corp (Jan 6, 2014). Both records have filings in the same period (Jan 6, 2014).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is CA or MA or OH or NJ or X0 or NH or NC or NY. A separate record, "Michael D. Ross" with address state MS, is listed on 1 filing — most recently by RENASANT CORP (Aug 4, 2010). Both records have filings in the same period (Aug 4, 2010).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is CA or MA or OH or NJ or X0 or NH or NC or NY. A separate record, "Michael L. Ross" with address state CA, is listed on 17 filings — most recently by MAKENA CAPITAL U.S. L P (Mar 22, 2010). Both records have filings in the same period (Feb 25, 2009 to Mar 22, 2010).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
Address moved from South San Francisco, CA to Sacramento, CA — Therini Bio, Inc. · Address moved from San Francisco, CA to South San Francisco, CA — Therini Bio, Inc. · Address moved from Princeton, NJ to New York, NY — Ophthotech Corp. · Address moved from Lebanon, NH to Waltham, MA — X4 Pharmaceuticals, Inc · Address moved from Boston, MA to Lebanon, NH — X4 Pharmaceuticals, Inc
What this means Businesses move. If you were told one city and the forms say another, ask which is current.
CA on 12 filings (Nov 29, 2010 to Nov 18, 2025); MA on 22 filings (Feb 7, 2011 to Feb 14, 2023); United Kingdom (as filed: X0) on 5 filings (Apr 27, 2012 to Aug 19, 2021); NH on 7 filings (Mar 15, 2013 to Jun 27, 2017); NJ on 1 filing (Jun 3, 2013); OH on 1 filing (Nov 25, 2015); NY on 1 filing (Nov 2, 2018); NC on 1 filing (Nov 19, 2018).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 64 filings (work cap); older filings are not covered here. As of Oct 24, 2026.
2 of 55 offerings report sales commissions totalling $2,150,000; 0 report finder's fees; 7 report proceeds to related persons totalling $5,462,460. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Nov 18, 2025 D Dualitas Therapeutics, Inc. File 021-564321 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 8, 2025 D/A Therini Bio, Inc. File 021-478843 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 26, 2024 D TRex Holdings Inc. File 021-530561 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 14, 2023 D Andovia Inc. File 021-473392 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 25, 2022 D SV Life Sciences Fund IV CF, L.P. File 021-438954 | $0 | $0 | $0 An affiliate of the general partner of the Issuer will receive a management fee payable by the Issuer quarterly in advance at an annual rate as specified in the Issuer's partnership agreement. | None listed on this filing | EDGAR ↗ |
| Aug 19, 2021 D Eyebiotech Ltd File 021-410579 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 26, 2021 D Xilio Therapeutics, Inc. File 021-390683 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 21, 2021 D Xilio Therapeutics, Inc. File 021-387002 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 22, 2020 D/A Therini Bio, Inc. File 021-339813 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 25, 2019 D SV7 Impact Medicine Fund LP File 021-342712 | $0 | $0 | $0 (est.) The Manager will receive a Management Fee as described in the Offering Documents. Amount is indeterminate at this time. | None listed on this filing | EDGAR ↗ |
| Nov 19, 2018 D Ribometrix, Inc. File 021-326066 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 2, 2018 D Ophthotech Corp. File 021-324993 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 8, 2018 D/A SUTRO BIOPHARMA INC File 021-314024 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 4, 2017 D X4 Pharmaceuticals, Inc File 021-300012 | $1,400,000 | $0 | $0 | Citigroup Global Markets Inc. BrokerCheck CRD 7059 ↗ Cowen and Company, LLC BrokerCheck CRD 7616 ↗ Piper Jaffray & Co. BrokerCheck CRD 665 ↗ | EDGAR ↗ |
| Oct 17, 2017 D/A Dementia Discovery LP File 021-249408 | $0 | $0 | $0 (est.) An affiliate of the general partner of the Issuer will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | None listed on this filing | EDGAR ↗ |
| Jun 27, 2017 D Avitide, Inc. File 021-289476 | $0 | $0 | $682,460 (est.) Includes salary and bonuses payable in the ordinary course of business. | None listed on this filing | EDGAR ↗ |
| Jun 5, 2017 D Deciphera Pharmaceuticals, LLC File 021-288027 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 8, 2017 D X4 Pharmaceuticals, Inc File 021-286233 | $0 | $0 | $3,000,000 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 12, 2017 D SV Life Sciences Fund VI Strategic Partners, L.P. File 021-284644 | $0 | $0 | $0 An affiliate of the general partner of the Issuer will receive a management fee payable by the Issuer quarterly in advance at an annual rate as specified in the Issuer's partnership agreement. | None listed on this filing | EDGAR ↗ |
| Oct 14, 2016 D/A AmeriClean Holdings LLC File 021-271539 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 14, 2016 D/A Deciphera Pharmaceuticals, LLC File 021-248413 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 26, 2016 D/A SV Life Sciences Fund VI, L.P. File 021-240550 | $0 | $0 | $0 (est.) An affiliate of the general partner of the Issuer will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | Crito Capital LLC BrokerCheck CRD 161724 ↗ | EDGAR ↗ |
| Apr 27, 2016 D X4 Pharmaceuticals, Inc File 021-262117 | $0 | $0 | $770,000 (est.) Ordinary course compensation for services. | None listed on this filing | EDGAR ↗ |
| Dec 30, 2015 D X4 Pharmaceuticals, Inc File 021-254201 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 25, 2015 D Lucina Health, Inc. File 021-251985 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 6, 2015 D Avitide, Inc. File 021-245207 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 5, 2015 D/A X4 Pharmaceuticals, Inc File 021-201235 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 31, 2015 D CATABASIS PHARMACEUTICALS INC File 021-236973 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 9, 2014 D Avitide, Inc. File 021-218775 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 24, 2014 D THESAN PHARMACEUTICALS, INC. File 021-212387 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 15, 2013 D CATABASIS PHARMACEUTICALS INC File 021-206457 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 27, 2013 D/A CATABASIS PHARMACEUTICALS INC File 021-191213 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 3, 2013 D Ophthotech Corp. File 021-197362 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 15, 2013 D Avitide, Inc. File 021-193359 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 4, 2013 D Lucina Health, Inc. File 021-189531 | $0 | $0 | $150,000 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 27, 2012 D Abcam plc File 021-177421 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 2, 2012 D Adimab, LLC File 021-176042 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 23, 2012 D Lucina Health, Inc. File 021-173835 | $0 | $0 | $260,000 (est.) | None listed on this filing | EDGAR ↗ |
| Oct 18, 2011 D Lucina Health, Inc. File 021-167477 | $0 | $0 | $150,000 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 20, 2011 D Link Medicine Corp File 021-158672 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Feb 7, 2011 D X4 Pharmaceuticals, Inc File 021-154945 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 29, 2010 D Adimab, Inc. File 021-151089 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 15, 2010 D Balance Health Corp File 021-150537 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 26, 2010 D JUVARIS BIO THERAPEUTICS INC File 021-149574 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 24, 2010 D X4 Pharmaceuticals, Inc File 021-148139 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 23, 2010 D/A Lucina Health, Inc. File 021-144992 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 30, 2010 D Link Medicine Corp File 021-141389 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 14, 2010 D CATABASIS PHARMACEUTICALS INC File 021-140570 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 7, 2010 D SV Life Sciences Fund V Strategic Partners, L.P. File 021-140268 | $0 | $0 | $0 (est.) The Issuer's fund manager will receive a fee for management services payable at an annual rate as specified in the Issuer's partnership agreement. | None listed on this filing | EDGAR ↗ |
| Mar 10, 2010 D/A SV LIFE SCIENCES FUND V LP File 021-129520 | $0 | $0 | $0 (est.) The Issuer's fund manager will receive a fee for management services payable at an annual rate as specified in the Issuer's partnership agreement. | None listed on this filing | EDGAR ↗ |
| Dec 9, 2009 D Ikano Therapeutics Inc. File 021-101585 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 6, 2009 D Adimab, Inc. File 021-106179 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 24, 2009 D JUVARIS BIO THERAPEUTICS INC File 021-84205 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 18, 2009 D Lucina Health, Inc. File 021-122668 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 29, 2008 D Link Medicine Corp File 021-76287 | $750,000 (est.) | $0 | $450,000 (est.) | MTS Securities, LLC BrokerCheck CRD 104059 ↗ via MTS Securities, MTS (CRD 104059 ↗) | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Michael Ross on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $32.6M from 7 investors (49% of the $66.6M target) as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $74.9M from 17 investors (93% of the $80.8M target) as of the latest filing. Michael is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $42.3M from 13 investors (50% of the $85M target) as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $632K from 1 investor (63% of the $1M target) as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $421.4M from 44 investors (100% of the $421.4M target) as of the latest filing. Michael is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $486 from 1 investor (100% of the $486 target) as of the latest filing. Michael is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $95M from 17 investors (100% of the $95M target) as of the latest filing. Michael is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Michael is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $15M from 16 investors (50% of the $30M target) as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $16.7M from 7 investors (100% of the $11.7M target) as of the latest filing. Michael is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $85.4M from 15 investors (100% of the $85.4M target) as of the latest filing. Michael is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $85M from 23 investors (100% of the $20M target) as of the latest filing. Michael is listed as director on 9 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $26M from 3 investors (9% of the $302.4M target) as of the latest filing. Michael is listed as executive officer on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $12M from 11 investors (100% of the $12M target) as of the latest filing. Michael is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $90.6M from 7 investors (100% of the $52.3M target) as of the latest filing. Michael is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $13.1M from 35 investors (100% of the $13.1M target) as of the latest filing. Michael is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $11M from 25 investors (100% of the $11M target) as of the latest filing. Michael is listed as executive officer, director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Retailing / 506(b) (959 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $273.5M from 24 investors (68% of the $400M target) as of the latest filing. Michael is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $4.52M from 10 investors (100% of the $1.76M target) as of the latest filing. Michael is listed as director on 7 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $175.7M from 23 investors (100% of the $20.4M target) as of the latest filing. Michael is listed as director on 5 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $17.4M from 5 investors (35% of the $49.5M target) as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $77M from 118 investors (100% of the $77M target) as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $13.8M from 12 investors (100% of the $13.8M target) as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $40M from 16 investors (100% of the $4.81M target) as of the latest filing. Michael is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $8.21M from 10 investors (100% of the $4M target) as of the latest filing. Michael is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $500K from 3 investors (100% of the $500K target) as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $15.1M from 3 investors (100% of the $2M target) as of the latest filing. Michael is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $10.6M from 68 investors (100% of the $10.6M target) as of the latest filing. Michael is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $407.2M from 42 investors (81% of the $500M target) as of the latest filing. Michael is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $893K from 14 investors as of the latest filing. Michael is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
SV Health Managers LLP is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Tillman U. Gerngross is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Terrance McGuire is on 21 issuers in total — a repeat sponsor. Their page lists every one.
Carl L. Gordon is on 62 issuers in total — a repeat sponsor. Their page lists every one.
Errik Anderson is on 17 issuers in total — a repeat sponsor. Their page lists every one.
David Guyer is on 9 issuers in total — a repeat sponsor. Their page lists every one.
Eugene D. Hill is on 11 issuers in total — a repeat sponsor. Their page lists every one.
Kate Bingham is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Amy Schulman is on 20 issuers in total — a repeat sponsor. Their page lists every one.
Nicholas Galakatos is on 32 issuers in total — a repeat sponsor. Their page lists every one.
James Garvey is on 10 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Listed on the same filings as Michael Ross. Their page shows their other deals.
Philip Ferneau is on 13 issuers in total — a repeat sponsor. Their page lists every one.
Koleman Karleski is on 5 issuers in total — a repeat sponsor. Their page lists every one.
David Milne is on 13 issuers in total — a repeat sponsor. Their page lists every one.
Paul LaViolette is on 20 issuers in total — a repeat sponsor. Their page lists every one.
Thomas Flynn is on 10 issuers in total — a repeat sponsor. Their page lists every one.
Daniel D Burgess is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Michael Ross. Their page shows their other deals.
One team, 10 deal companies. Michael Ross is listed on 7 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Michael Ross.
One team, 2 deal companies. Michael Ross is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Michael Ross.
One team, 2 deal companies. Michael Ross is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Michael Ross.
One team, 16 deal companies. Michael Ross is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Michael Ross.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).
A person is never an adviser firm. 2 of the 30 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): SV7 Impact Medicine Fund LP, Dementia Discovery LP.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Michael Ross by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 30 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Michael Ross is listed on: none on file. No website or social profile named in SV Life Sciences Fund IV CF, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #160,494 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (Boston, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Michael Ross appears on a new Form D, or when a court case or SEC action is matched to them. See plans →